s6y

Neurogene Inc.

Ticker
NGNE
CIK
1404644
Industry
Pharmaceutical Preparations
Formerly
Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC

Financials 54

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending Sep 30, 2024

All 54 financials filings

News 153

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 153 news filings

Ownership 382

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4/A Statement of changes in beneficial ownership of securities
  5. 4/A Statement of changes in beneficial ownership of securities
  6. 4/A Statement of changes in beneficial ownership of securities
  7. 3/A Initial statement of beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 382 ownership filings

Prospectus 54

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. S-3 Registration statement for specified transactions by certain issuers
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. S-1 General form of registration statement for all companies including face-amount certificate companies
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 54 prospectus filings

Proxies 27

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 27 proxies filings

Other 86

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G/A
  4. SCHEDULE 13G/A
  5. SCHEDULE 13G
  6. SCHEDULE 13G
  7. SCHEDULE 13G/A
  8. SCHEDULE 13G
  9. SCHEDULE 13G/A
  10. 144 Filing for proposed sale of securities under Rule 144

All 86 other filings